James Hardie Industries plc. Ordinary Shares vs Smith & Nephew plc — how do they compare? James Hardie Industries plc. Ordinary Shares trades at $25.12 (market cap $14.60B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: James Hardie Industries plc. Ordinary Shares is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while James Hardie Industries plc. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold James Hardie Industries plc. Ordinary Shares for 1 Days and Smith & Nephew plc for 121 Days on average.
| JHX | SNN | |
|---|---|---|
Market Cap | $14.60B | $11.10B |
Volume | 7,262,924 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $31.08 | $37.17 |
52-Week Low | $16.69 | $26.42 |
Typical Hold Time | 1 Days | 121 Days |
Enterprise Value | $18.83B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Trailing returns across standard periods
James Hardie manufactures fiber cement products for residential and commercial construction. Its portfolio includes exterior siding, interior boards, and other building materials.
Read more on JHX →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →